Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
Mathieu Gigoux, Morten O. Holmström, Roberta Zappasodi, Joseph J. Park, Stephane Pourpe, Cansu Cimen Bozkus, Levi M.B. Mangarin, David Redmond, Svena Verma, Sara Schad, Mariam M. George, Divya Venkatesh, Arnab Ghosh, David Hoyos, Zaki Molvi, Baransel Kamaz, Anna E. Marneth, William Duke, Matthew J. Leventhal, Max JanVincent T. Ho, Gabriela S. Hobbs, Trine Alma Knudsen, Vibe Skov, Lasse Kjær, Thomas Stauffer Larsen, Dennis Lund Hansen, R. Coleman Lindsley, Hans Hasselbalch, Jacob H. Grauslund, Thomas L. Lisle, Özcan Met, Patrick Wilkinson, Benjamin Greenbaum, Manuel A. Sepulveda, Timothy Chan, Raajit Rampal, Mads H. Andersen, Omar Abdel-Wahab, Nina Bhardwaj, Jedd D. Wolchok, Ann Mullally, Taha Merghoub
Dive into the research topics of 'Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine'. Together they form a unique fingerprint.